Products Details

Product Description

– BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1].

Web ID

– HY-W423595

Shipping

– Room temperature

Applications

– Cancer-Kinase/protease

Molecular Formula

– C27H32N8O3

References

– [1]Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14(2):100961.

CAS Number

– 2050906-40-4

Molecular Weight

– 516.59

SMILES

– C=CC(NC1=CC(NC2=NC=CC(N3C=CC4=NC(OC)=CC=C43)=N2)=C(OC)C=C1N(CCN(C)C)C)=O

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– EGFR

Pathway

– JAK/STAT Signaling, Protein Tyrosine Kinase/RTK

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=